MA43943A - Compositions et procédés pour traiter des patients avec des cellules mutantes rtk - Google Patents
Compositions et procédés pour traiter des patients avec des cellules mutantes rtkInfo
- Publication number
- MA43943A MA43943A MA043943A MA43943A MA43943A MA 43943 A MA43943 A MA 43943A MA 043943 A MA043943 A MA 043943A MA 43943 A MA43943 A MA 43943A MA 43943 A MA43943 A MA 43943A
- Authority
- MA
- Morocco
- Prior art keywords
- compositions
- methods
- treating patients
- mutant cells
- rtk
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/10—Transferases (2.)
- C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biophysics (AREA)
- Cell Biology (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Microbiology (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Analytical Chemistry (AREA)
- Pathology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Oncology (AREA)
- Physics & Mathematics (AREA)
- Hospice & Palliative Care (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201562168237P | 2015-05-29 | 2015-05-29 | |
US201662309900P | 2016-03-17 | 2016-03-17 |
Publications (1)
Publication Number | Publication Date |
---|---|
MA43943A true MA43943A (fr) | 2018-12-12 |
Family
ID=57441630
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA043943A MA43943A (fr) | 2015-05-29 | 2016-05-25 | Compositions et procédés pour traiter des patients avec des cellules mutantes rtk |
Country Status (9)
Country | Link |
---|---|
US (2) | US20180177792A1 (fr) |
EP (1) | EP3303382A4 (fr) |
JP (2) | JP6929231B2 (fr) |
CN (1) | CN107849113B (fr) |
AU (1) | AU2016270321B2 (fr) |
CA (1) | CA2987281A1 (fr) |
HK (1) | HK1252821A1 (fr) |
MA (1) | MA43943A (fr) |
WO (1) | WO2016196141A1 (fr) |
Families Citing this family (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
RS53350B (en) | 2008-09-22 | 2014-10-31 | Array Biopharma, Inc. | SUBSTITUTED COMPOUNDS OF IMIDASO [1,2-B] PYRIDASINE AS INK KINASE INHIBITORS |
SG10201914059WA (en) | 2008-10-22 | 2020-03-30 | Array Biopharma Inc | Substituted pyrazolo[1,5-a]pyrimidine compounds as trk kinase inhibitors |
AR077468A1 (es) | 2009-07-09 | 2011-08-31 | Array Biopharma Inc | Compuestos de pirazolo (1,5 -a) pirimidina sustituidos como inhibidores de trk- quinasa |
SG10201506591TA (en) | 2010-05-20 | 2015-09-29 | Array Biopharma Inc | Macrocyclic compounds as trk kinase inhibitors |
TWI672141B (zh) | 2014-02-20 | 2019-09-21 | 美商醫科泰生技 | 投予ros1突變癌細胞之分子 |
CN107428760B (zh) | 2014-11-16 | 2021-04-27 | 阵列生物制药公司 | (s)-n-(5-((r)-2-(2,5-二氟苯基)-吡咯烷-1-基)-吡唑并[1,5-a]嘧啶-3-基)-3-羟基吡咯烷-1-甲酰胺硫酸氢盐的晶型 |
CN107207471B (zh) | 2014-12-02 | 2020-06-26 | 伊尼塔公司 | 用于治疗神经母细胞瘤的组合 |
CA3003153A1 (fr) | 2015-10-26 | 2017-05-04 | Loxo Oncology, Inc. | Mutations ponctuelles dans le cancer resistant aux inhibiteurs de trk et methodes associees |
BR112018012255A2 (pt) | 2015-12-18 | 2018-12-04 | Ignyta Inc | método para tratar câncer |
UA125026C2 (uk) | 2016-04-04 | 2021-12-29 | Локсо Онколоджі, Інк. | РІДКІ КОМПОЗИЦІЇ (S)-N-(5-((R)-2-(2,5-ДИФТОРФЕНІЛ)ПІРОЛІДИН-1-ІЛ)ПІРАЗОЛО[1,5-a]ПІРИМІДИН-3-ІЛ)-3-ГІДРОКСИПІРОЛІДИН-1-КАРБОКСАМІДУ |
US10045991B2 (en) | 2016-04-04 | 2018-08-14 | Loxo Oncology, Inc. | Methods of treating pediatric cancers |
AU2017246547B2 (en) | 2016-04-04 | 2023-02-23 | Loxo Oncology, Inc. | Methods of treating pediatric cancers |
UA127826C2 (uk) | 2016-05-18 | 2024-01-17 | Локсо Онколоджі, Інк. | СПОСІБ ОДЕРЖАННЯ (S)-N-(5-((R)-2-(2,5-ДИФТОРФЕНІЛ)ПІРОЛІДИН-1-ІЛ)-ПІРАЗОЛО[1,5-а]ПІРИМІДИН-3-ІЛ)-3-ГІДРОКСИПІРОЛІДИН-1-КАРБОКСАМІДУ |
JOP20190092A1 (ar) | 2016-10-26 | 2019-04-25 | Array Biopharma Inc | عملية لتحضير مركبات بيرازولو[1، 5-a]بيريميدين وأملاح منها |
JOP20190213A1 (ar) | 2017-03-16 | 2019-09-16 | Array Biopharma Inc | مركبات حلقية ضخمة كمثبطات لكيناز ros1 |
CA3069339A1 (fr) | 2017-07-19 | 2019-01-24 | Ignyta, Inc. | Compositions pharmaceutiques contenant de l'entrectinib |
CN111225662B (zh) | 2017-10-17 | 2022-11-22 | 伊尼塔公司 | 药物组合物和剂型 |
CN111818915B (zh) | 2018-01-31 | 2024-05-24 | 德西费拉制药有限责任公司 | 治疗胃肠道间质瘤的组合疗法 |
EP4013412A1 (fr) | 2019-08-12 | 2022-06-22 | Deciphera Pharmaceuticals, LLC | Ripretinib pour le traitement de tumeurs stromales gastro-intestinales |
WO2021030405A1 (fr) | 2019-08-12 | 2021-02-18 | Deciphera Pharmaceuticals, Llc | Ripretinib pour le traitement de tumeurs stromales gastro-intestinales |
CN110643672A (zh) * | 2019-10-15 | 2020-01-03 | 西安交通大学 | 高表达TrkB作为新型靶点在抑制胰腺癌转移方面的医药用途 |
KR20220123057A (ko) | 2019-12-30 | 2022-09-05 | 데시페라 파마슈티칼스, 엘엘씨. | 비정질 키나아제 억제제 제형 및 이의 사용 방법 |
EP4084779A1 (fr) | 2019-12-30 | 2022-11-09 | Deciphera Pharmaceuticals, LLC | Compositions de 1-(4-bromo-5-(1-éthyl-7-(méthylamino)-2-oxo-1,2-dihydro -1,6-naphthyridine-3-yl)-2-fluorophényl)-3-phényluree |
WO2021178789A1 (fr) * | 2020-03-06 | 2021-09-10 | Deciphera Pharmaceuticals, Llc | Procédés d'utilisation de rebastinib dans le traitement de différents troubles cancéreux |
US11779572B1 (en) | 2022-09-02 | 2023-10-10 | Deciphera Pharmaceuticals, Llc | Methods of treating gastrointestinal stromal tumors |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2002275068A (ja) * | 2001-03-16 | 2002-09-25 | Kyowa Hakko Kogyo Co Ltd | アポトーシス誘導剤 |
NZ547398A (en) * | 2003-10-24 | 2008-10-31 | Esbatech Ag | Method for the identification and/or validation of receptor tyrosine kinase inhibitors |
WO2006111035A1 (fr) * | 2005-04-21 | 2006-10-26 | Oncalis Ag | Methode d'identification de mutations potentiellement dangereuses du recepteur tyrosine kinase (rtk) et d'inhibiteurs ou de medicaments diriges contre les mutants de rtk |
RU2008108889A (ru) * | 2005-08-09 | 2009-09-20 | Иоганнес Гутенберг-Университэт Майнц (De) | Сенсибилизация к ингибиторам протеинкиназ устойчивого к лекарственным средствам рака легкого |
US20110008347A1 (en) * | 2006-12-01 | 2011-01-13 | Agency For Science ,Technology And Research | Cancer-related protein kinases |
CA2693901C (fr) * | 2007-07-20 | 2015-12-29 | Nerviano Medical Sciences S.R.L. | Derives d'indazole substitues actifs comme inhibiteurs de kinases |
JP5758289B2 (ja) * | 2008-05-21 | 2015-08-05 | サントル、ナショナール、ド、ラ、ルシェルシュ、シアンティフィク、(セーエヌエルエス) | NT−3:TrkC結合の阻害および神経芽腫などの癌の処置へのその適用 |
SG10201914059WA (en) * | 2008-10-22 | 2020-03-30 | Array Biopharma Inc | Substituted pyrazolo[1,5-a]pyrimidine compounds as trk kinase inhibitors |
US8383793B2 (en) * | 2010-04-15 | 2013-02-26 | St. Jude Children's Research Hospital | Methods and compositions for the diagnosis and treatment of cancer resistant to anaplastic lymphoma kinase (ALK) kinase inhibitors |
WO2012116217A1 (fr) * | 2011-02-25 | 2012-08-30 | Irm Llc | Composés et compositions en tant qu'inhibiteurs de trk |
CN102924479A (zh) * | 2011-08-09 | 2013-02-13 | 山东鲁北药业有限公司 | 一种星孢菌素类衍生物的半合成方法 |
-
2016
- 2016-05-25 US US15/577,729 patent/US20180177792A1/en not_active Abandoned
- 2016-05-25 MA MA043943A patent/MA43943A/fr unknown
- 2016-05-25 CN CN201680040063.7A patent/CN107849113B/zh active Active
- 2016-05-25 WO PCT/US2016/034166 patent/WO2016196141A1/fr active Application Filing
- 2016-05-25 EP EP16804039.2A patent/EP3303382A4/fr active Pending
- 2016-05-25 JP JP2017560654A patent/JP6929231B2/ja active Active
- 2016-05-25 CA CA2987281A patent/CA2987281A1/fr not_active Abandoned
- 2016-05-25 AU AU2016270321A patent/AU2016270321B2/en not_active Withdrawn - After Issue
-
2018
- 2018-09-20 HK HK18112149.5A patent/HK1252821A1/zh unknown
-
2021
- 2021-06-01 JP JP2021092592A patent/JP7219791B2/ja active Active
- 2021-06-23 US US17/356,128 patent/US20210322439A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
CN107849113B (zh) | 2022-03-22 |
JP2018521973A (ja) | 2018-08-09 |
JP6929231B2 (ja) | 2021-09-01 |
US20210322439A1 (en) | 2021-10-21 |
AU2016270321B2 (en) | 2020-09-10 |
JP2021156893A (ja) | 2021-10-07 |
US20180177792A1 (en) | 2018-06-28 |
EP3303382A4 (fr) | 2018-12-19 |
WO2016196141A1 (fr) | 2016-12-08 |
HK1252821A1 (zh) | 2019-06-06 |
AU2016270321A2 (en) | 2018-01-04 |
AU2016270321A1 (en) | 2017-12-14 |
CN107849113A (zh) | 2018-03-27 |
CA2987281A1 (fr) | 2016-12-08 |
EP3303382A1 (fr) | 2018-04-11 |
JP7219791B2 (ja) | 2023-02-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MA43943A (fr) | Compositions et procédés pour traiter des patients avec des cellules mutantes rtk | |
HK1243333A1 (zh) | 用於修飾的t細胞的方法和組合物 | |
MA45408A (fr) | Compositions et procédés pour la déplétion des cellules cd117+ | |
HK1244841A1 (zh) | 用於選擇性消除所關注細胞的方法和組合物 | |
HK1244826A1 (zh) | 用於過繼細胞治療的方法和組合物 | |
HK1232141A1 (zh) | 用於治療亨廷頓病的方法和組合物 | |
HK1245080A1 (zh) | 自然殺傷細胞的方法和組合物 | |
HK1243942A1 (zh) | 舒尼替尼製劑及其在治療青光眼中的使用方法 | |
IL251576A0 (en) | Methods and compositions for creating or maintaining multifunctional cells | |
IL263743A (en) | Cell depletion compositions and methods | |
DK3102673T3 (da) | Fremgangsmåder og sammensætninger til behandling af beta-talassæmi | |
IL246791A0 (en) | Compositions and methods for treating eye diseases | |
HUE055913T2 (hu) | Módszerek és készítmények a glioblastoma diagnosztizálására és kezelésére | |
EP3229849A4 (fr) | Compositions d'additifs pour la désinfection pigmentée et procédés correspondants | |
HK1232152A1 (zh) | 用於治療異常細胞生長的方法和組合物 | |
GB201400442D0 (en) | Compositions for use in the treatment of ulcerative colitis | |
PL3166911T3 (pl) | Wprowadzanie czynników biologicznych do nawozów | |
DK3110446T3 (da) | Fremgangsmåder og sammensætninger til behandling af Siglec-8-associerede sygdomme | |
ZA201606199B (en) | Compositions and methods for treating diabetes and liver diseases | |
HK1259083A1 (zh) | 用於治療系統性肥大細胞增多症的方法和組合物 | |
WO2016014319A9 (fr) | Compositions et procédés d'enrichissement de confinement d'animaux | |
HK1246206A1 (zh) | 用於治療青光眼的組合物和方法 | |
IL246667A0 (en) | Preparations and methods for the treatment of abnormal cell growth | |
PL3232789T3 (pl) | Tabletki do uzdatniania i dezynfekcji wody | |
DK3229790T3 (da) | Sammensætninger omfattende mediumkæde triglycerider til anvendelse i behandlingen af epilepsi |